Chris Boshoff
克里斯·博肖夫
MD, PhD, FMedSci
Chief Scientific Officer, Pfizer Oncology; formerly Director, Center for Cancer Genomics, NCI/NIH辉瑞肿瘤首席科学官；前NCI/NIH癌症基因组学中心主任
👥Biography 个人简介
Chris Boshoff, MD, PhD, FMedSci is Chief Scientific Officer of Pfizer Oncology, and formerly served as Director of the Center for Cancer Genomics at the National Cancer Institute (NCI), NIH, one of the most prominent leadership positions in academic cancer genomics. As NCI Center Director, Dr. Boshoff oversaw The Cancer Genome Atlas (TCGA), the Genomic Data Commons (GDC), and major computational oncology infrastructure programs that have generated and made publicly available genomic data on over 33,000 cancer patients across 80+ tumor types, constituting the world's largest and most influential cancer genomics resource. His scientific career began with landmark discoveries in viral oncology, including identifying the oncogenic mechanisms of Kaposi Sarcoma Herpesvirus (KSHV/HHV-8), characterizing its latency genes, cyclin D homolog (vCyclin), FLIP anti-apoptotic proteins, and viral G-protein coupled receptor (vGPCR) as oncogenic drivers, work published in Science, Nature, and Cell that established KSHV molecular virology as a field. After building a distinguished academic program at University College London's Cancer Research UK Centre, Dr. Boshoff joined NCI to lead the national cancer genomics portfolio, overseeing TCGA pan-cancer analyses including the seminal Cell 2018 TCGA Pan-Cancer Atlas publication series that comprehensively characterized the molecular landscape of human cancer. He subsequently joined Pfizer to apply these genomic insights to oncology drug development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
TCGA Pan-Cancer Atlas — Comprehensive Molecular Landscape of Human Cancer
As NCI Director of the Center for Cancer Genomics, oversaw the completion of The Cancer Genome Atlas Pan-Cancer Atlas project and the landmark Cell 2018 paper series (29 papers in a coordinated Cell issue) that comprehensively characterized the genomic, epigenomic, transcriptomic, and proteomic landscapes of 33 cancer types across 11,000+ patients. This resource established the reference molecular taxonomy of human cancer, identifying pan-cancer driver genes, mutation signatures, immune subtypes, and oncogenic pathway activations used by virtually every computational oncology study worldwide.
Kaposi Sarcoma Herpesvirus — Oncogenic Mechanisms and Viral Cancer Biology
Made seminal contributions to understanding KSHV/HHV-8 oncogenesis, identifying and characterizing the viral cyclin D homolog (vCyclin), viral FLIP anti-apoptotic protein (vFLIP), and viral G-protein coupled receptor (vGPCR) as key oncogenic drivers of Kaposi sarcoma. Published landmark mechanistic studies in Nature, Science, and Cell demonstrating how KSHV hijacks cell cycle regulation, apoptosis pathways, and angiogenic signaling, establishing KSHV as a model for viral oncogenesis and identifying potential therapeutic targets for AIDS-associated malignancies.
Genomic Data Commons — Cancer Genomics Infrastructure and Open Data
Directed the development and launch of the NCI Genomic Data Commons (GDC), the national harmonized cancer genomics data repository that standardizes and provides open access to TCGA, TARGET, CGCI, and other NCI genomics datasets with uniform data processing pipelines. The GDC has enabled hundreds of large-scale computational oncology studies by providing analysis-ready genomic data with consistent quality control, variant calling, and clinical annotation, becoming the essential infrastructure for translational cancer genomics research globally.
Translational Cancer Genomics for Drug Development at Pfizer
Applied cancer genomics expertise at Pfizer Oncology to guide target identification, patient stratification biomarker development, and clinical trial design using genome-wide computational approaches. Led initiatives integrating genomic biomarkers into oncology clinical programs to identify molecular predictors of drug response, applying computational oncology methods from the TCGA era to pharmaceutical drug development and accelerating precision oncology asset development.
Representative Works 代表性著作
The Cancer Genome Atlas Pan-Cancer Analysis Project
Nature Genetics (2013)
Overview of the TCGA Pan-Cancer Analysis project coordinating genomic characterization of 12 cancer types, establishing the foundation for comprehensive cancer genomics reference resources.
A Cell Cycle Regulatory Protein (vCyclin) Encoded by Kaposi Sarcoma Herpesvirus
Nature (1996)
Discovery of the KSHV viral cyclin D homolog (vCyclin) demonstrating that Kaposi sarcoma herpesvirus encodes an oncogenic cyclin that promotes cell cycle progression through CDK6 interaction.
Viral Interleukin-6 (vIL-6) and Viral G Protein-Coupled Receptor (vGPCR) in KSHV Pathogenesis
Science (1998)
Characterization of KSHV vGPCR oncogenesis, demonstrating constitutively active signaling driving KS tumorigenesis through VEGF-dependent and independent mechanisms.
Comprehensive Molecular Portraits of Human Breast Tumours (TCGA)
Nature (2012)
Landmark TCGA analysis of 825 breast cancers characterizing molecular subtypes across genomic, transcriptomic, proteomic, and epigenomic platforms, establishing the reference breast cancer molecular taxonomy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Faisal Mahmood
Brigham and Women's Hospital; Harvard Medical School
Kun-Hsing Yu
Harvard Medical School; Brigham and Women's Hospital
Ziad Obermeyer
University of California, Berkeley; UC San Francisco
Andrew H. Beck
PathAI; Harvard Medical School (formerly)
关注 克里斯·博肖夫 的研究动态
Follow Chris Boshoff's research updates
留下邮箱，当我们发布与 Chris Boshoff（Pfizer Oncology; formerly National Cancer Institute (NCI), NIH）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment